GoodRx price target raised to $6 from $5.50 at Wells Fargo

Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on GoodRx to $6 from $5.50 and keeps an Equal Weight rating on the shares. The stock is "unlikely to work" until management can show consistent customer growth and price stabilization, Gold member growth, and improved PM Solutions, the analyst tells investors in a research note. The firm believes these trends are unlikely to emerge before late 2023/early 2024.